中信证券股份有限公司 关于北京键凯科技股份有限公司 首次公开发行限售股上市流通的核查意见 中信证券股份有限公司（以下简称"中信证券"或"保荐机构"）作为北京 键凯科技股份有限公司（以下简称"公司"、"键凯科技"或"发行人"）首次公 开发行股票并在科创板上市的保荐机构。根据《证券发行上市保荐业务管理办法》 《上海证券交易所科创板股票上市规则》以及《科创板上市公司持续监管办法（试 行）》等有关规定，对公司首次公开发行限售股上市流通事项进行了核查，核查 情况如下： 2020 年 7 月 28 日，中国证券监督管理委员会出具《关于同意北京键凯科技 股份有限公司首次公开发行股票注册的批复》（证监许可[2020]1579 号），同意公 司首次向社会公开发行人民币普通股（A 股）1,500 万股（以下简称"首次公开 发行"），并于 2020 年 8 月 26 日在上海证券交易所科创板挂牌上市。公司首次公 开发行后总股本为 60,000,000 股，其中有限售条件流通股 46,358,399 股，无限售 条件流通股 13,641,601 股。公司首次公开发行的网下配售的 608,399 股限售股已 于 2021 年 2 月 ...

Financial Performance - The company reported a revenue of CNY 92,823,711.88 for Q1 2023, representing a year-over-year decrease of 7.95%[5] - Net profit attributable to shareholders was CNY 47,081,919.93, down 10.04% compared to the same period last year[5] - The net profit after deducting non-recurring gains and losses was CNY 43,513,875.16, showing a slight increase of 0.73% year-over-year[5] - Basic earnings per share were CNY 0.78, down 10.34% year-over-year[6] - The net profit for Q1 2023 was CNY 47,081,919.93, down 10.67% from CNY 52,338,062.73 in Q1 2022[18] - The total comprehensive income for Q1 2023 was CNY 46,437,814.52, compared to CNY 51,952,638.01 in Q1 2022[18] Cash Flow - The net cash flow from operating activities was CNY 39,121,377.13, reflecting a decrease of 13.73% compared to the previous year[6] - In Q1 2023, the company's cash inflow from operating activities was CNY 104,689,131.23, an increase of 6.4% compared to CNY 98,319,856.82 in Q1 2022[19] - The net cash flow from operating activities decreased to CNY 39,121,377.13, down 13.5% from CNY 45,349,764.61 in the same period last year[19] - Cash inflow from investment activities was CNY 197,518,140.32, a decrease of 28.6% compared to CNY 276,713,534.05 in Q1 2022[19] - The net cash flow from investment activities was -CNY 140,153,008.76, worsening from -CNY 8,644,110.42 in Q1 2022[19] - The company recorded a net increase in cash and cash equivalents of -CNY 98,645,162.09, compared to a positive increase of CNY 35,182,529.81 in the previous year[19] - The ending balance of cash and cash equivalents was CNY 202,316,882.85, down from CNY 263,039,542.62 at the end of Q1 2022[19] - Total cash outflow from operating activities was CNY 65,567,754.10, an increase of 23.8% from CNY 52,970,092.21 in the same quarter last year[19] - The company obtained CNY 5,000,000.00 in loans during the quarter, with a net cash flow from financing activities of CNY 3,733,121.08[19] Assets and Liabilities - Total assets at the end of the reporting period were CNY 1,338,167,702.38, an increase of 2.73% from the end of the previous year[6] - The company's cash and cash equivalents decreased to CNY 209,460,204.13 from CNY 309,629,593.24 at the end of 2022[15] - Total assets increased to CNY 1,338,167,702.38 as of March 31, 2023, compared to CNY 1,302,559,885.18 at the end of 2022[16] - The total liabilities decreased to CNY 61,465,026.38 from CNY 77,801,659.23 at the end of 2022[16] Research and Development - R&D expenses totaled CNY 13,302,499.84, a decrease of 30.47% compared to the same period last year[6] - R&D expenses accounted for 14.33% of revenue, down 4.64 percentage points year-over-year[6] - R&D expenses for the quarter amounted to CNY 13,302.50 million, a decrease of 30.47% compared to CNY 19,130.96 million in the same period last year[18] Shareholder Information - The company had a total of 5,472 common shareholders at the end of the reporting period[10] Sales Performance - Product sales revenue was CNY 7,653.43 million, down 15.09% year-over-year, while technical service revenue increased by 51.99% to CNY 1,612.06 million[13] - The company reported a decrease in foreign sales revenue by 22.67% to CNY 4,761.26 million, attributed to logistics delays and a significant drop in LNP product orders[13] Other Financial Metrics - The weighted average return on equity was 3.76%, a decrease of 1.09 percentage points compared to the previous year[6] - The company confirmed share-based payment expenses of CNY 627.47 million, down from CNY 893.19 million in the previous year[13] - The company received CNY 11,073,557.52 in tax refunds, significantly higher than CNY 4,822,238.45 in Q1 2022, marking an increase of 129.8%[19] - The company did not report any net profit from the merged entity prior to the merger, consistent with the previous period[19]

重要内容提示： 投资者可于 2023 年 04 月 18 日(星期二)至 04 月 24 日(星期一)16:00 前登录 上证路演中心网站首页点击"提问预征集"栏目或通过公司邮箱 ir@jenkem.com 进行提问。公司将在说明会上对投资者普遍关注的问题进行回答。 北京键凯科技股份有限公司（以下简称"公司"）已于 2023 年 3 月 31 日发 布公司 2022 年年度报告，为便于广大投资者更全面深入地了解公司 2022 年度经 营成果、财务状况，公司计划于 2023 年 04 月 25 日下午 14:00-15:00 举行 2022 年度业绩说明会，就投资者关心的问题进行交流。 一、说明会类型 本次投资者说明会以网络互动形式召开，公司将针对 2022 年度的经营成果 及财务指标的具体情况与投资者进行互动交流和沟通，在信息披露允许的范围内 就投资者普遍关注的问题进行回答。 二、说明会召开的时间、地点 证券代码：688356 证券简称：键凯科技 公告编号：2023-017 北京键凯科技股份有限公司 关于召开 2022 年度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 ...

北京键凯科技股份有限公司 投资者关系活动记录表 | --- | --- | --- | --- | |-------------------------|-----------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ...

证券代码：688356 证券简称：键凯科技 单位：元 币种：人民币 2022 年第三季度报告 北京键凯科技股份有限公司 2022 年第三季度报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整， 不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 公司负责人、主管会计工作负责人及会计机构负责人（会计主管人员）保证季度报告中财务 信息的真实、准确、完整。 第三季度财务报表是否经审计 □是 √否 一、 主要财务数据 (一)主要会计数据和财务指标 本报告期 年初至报告期 | --- | --- | --- | --- | --- | |------------------------------------------------|----------------|------------------------------|----------------|------------------------------ ...

Financial Performance - The company reported a revenue of RMB 500 million for the first half of 2022, representing a year-on-year increase of 20%[2]. - The company's operating revenue for the first half of 2022 was approximately ¥214.77 million, representing a year-on-year increase of 37.91% compared to ¥155.74 million in the same period last year[26]. - The net profit attributable to shareholders for the same period was approximately ¥111.40 million, reflecting a growth of 38.15% from ¥80.64 million year-on-year[26]. - The gross margin for the first half of 2022 was reported at 45%, a slight increase from 42% in the same period last year[2]. - The comprehensive gross margin for the first half of 2022 was 85.20%, an increase of 0.51 percentage points from the same period in 2021[62]. - The net cash flow from operating activities surged by 173.07%, reaching approximately ¥151.14 million, compared to ¥55.35 million in the previous year[26]. - Total assets increased by 8.11% to approximately ¥1.19 billion, while net assets attributable to shareholders grew by 7.41% to approximately ¥1.13 billion[26]. - Basic earnings per share rose by 38.81% to ¥1.86, while diluted earnings per share increased by 37.31% to ¥1.84[26]. Research and Development - Research and development efforts focused on new technologies, with an investment of RMB 50 million in the development of lipid nanoparticles (LNPs) for drug delivery systems[2]. - Research and development expenses accounted for 19.99% of operating revenue, up from 11.64% in the previous year, indicating a significant increase of 8.35 percentage points[26]. - The total R&D investment increased by 136.82% year-on-year, amounting to ¥42,936,514.43, with R&D expenses accounting for 19.99% of operating revenue, up from 11.64%[49][50]. - The number of R&D personnel increased from 35 to 61, representing 26.18% of the total workforce, with an average salary of ¥12.33[57]. - The company completed the development of 61 new structural derivatives and 60 analytical methods during the reporting period, enhancing its technological capabilities[58]. - The company has applied for 16 new invention patents during the reporting period, with a total of 61 applications and 96 patents granted[48]. - The company aims to complete clinical trials for JK-2122H and continue clinical research for JK-1119I, which has received ¥11,853,508.40 in current period investment[54]. Market Expansion and Product Development - The company provided a future outlook, projecting a revenue growth of 25% for the second half of 2022, driven by new product launches and market expansion[2]. - The company plans to expand its market presence in Southeast Asia, targeting a 10% market share by the end of 2023[2]. - A strategic acquisition of a local biotech firm is expected to enhance the company's product portfolio and increase market competitiveness[2]. - The company aims to launch three new products in the next quarter, which are anticipated to contribute an additional RMB 100 million in revenue[2]. - The company has developed innovative PEG-modified drugs and medical devices, which are currently in preclinical or Phase II clinical research stages[31]. - The company has developed several PEG-modified drugs and Class III medical devices, including PEG-irinotecan, which has entered Phase II clinical trials, and the medical device project JK-2122H, which is currently in clinical stages[34]. Environmental Commitment - The company emphasizes its commitment to environmental protection, adhering to national and local regulations during production[98]. - Key pollutants generated during production include wastewater, waste gas, and noise, with effective treatment measures implemented[98]. - The company operates five high exhaust stacks for waste gas, ensuring emissions meet regulatory standards[98]. - The company’s wastewater treatment system effectively handles production wastewater and domestic sewage, ensuring compliance with environmental regulations[104]. - The company has a comprehensive environmental management system in place, including protocols for hazardous waste disposal and environmental risk assessments[110]. Shareholder and Governance Policies - The company reported a commitment to not transfer or manage shares for 36 months post-IPO, with an automatic extension of 6 months if stock prices fall below the IPO price for 20 consecutive trading days within the first 6 months[121]. - Shareholders are restricted from transferring shares for 12 months post-IPO, ensuring stability during the initial trading period[123]. - The company will comply with regulations regarding share transfers and will publicly apologize if commitments are not fulfilled, with potential compensation for losses incurred by investors[125]. - The company has committed to a profit distribution policy that emphasizes reasonable returns to investors, ensuring that cash dividends will account for at least 80% of profits during mature stages without significant capital expenditures[156]. - The company will prioritize cash dividends when conditions allow, with stock dividends being considered only when the stock price is deemed misaligned with the company's capital structure[159]. - The company will maintain a continuous and stable profit distribution policy, taking into account the opinions of independent directors and public investors[156]. Financial Management and Investments - The company has utilized a total of RMB 154,649,800 in cash management from raised funds, with an expected annualized return rate ranging from 1.78% to 3.29% across various investment products[180][182][183]. - The company has invested in various financial products, including structured deposits and wealth management products, with a focus on capital preservation and liquidity[180][182]. - The company’s cash management strategy includes investments in safe and liquid products, ensuring the security of raised funds[180]. - The total amount used for share buybacks in a single fiscal year cannot exceed 50% of the net profit attributable to the parent company from the previous year[141].

Financial Performance - The company's revenue for Q1 2022 reached ¥100,845,422.03, representing a 44.23% increase compared to the same period last year[6] - Net profit attributable to shareholders was ¥52,338,062.73, reflecting a growth of 45.41% year-over-year[6] - Basic earnings per share (EPS) for the period was ¥0.87, up by 45.00% from the same quarter last year[6] - The company achieved a revenue of 100.84 million yuan in Q1 2022, representing a year-over-year growth of 44.23%[22] - Net profit attributable to shareholders reached 52.34 million yuan, up 45.41% compared to the previous year[22] - The company's operating profit for Q1 2022 was ¥59,295,556.46, an increase of 41.5% compared to ¥41,925,586.26 in Q1 2021[29] - Total comprehensive income for Q1 2022 was ¥51,952,638.01, compared to ¥35,552,598.07 in Q1 2021, reflecting a growth of 46%[29] Cash Flow - The net cash flow from operating activities surged to ¥45,349,764.61, a significant increase of 626.35% compared to the previous year[6] - Cash inflow from operating activities totaled ¥98,319,856.82 in Q1 2022, significantly higher than ¥43,551,510.57 in Q1 2021, marking a 125.5% increase[29] - The net cash flow from operating activities for Q1 2022 was ¥45,349,764.61, compared to ¥6,243,487.18 in Q1 2021, indicating a substantial improvement[31] - Cash flow from investing activities showed a net outflow of ¥8,644,110.42 in Q1 2022, an improvement from a net outflow of ¥283,369,778.66 in Q1 2021[31] - The company reported cash and cash equivalents of ¥263,039,542.62 at the end of Q1 2022, up from ¥432,074,402.33 at the end of Q1 2021[31] Research and Development - Total R&D investment amounted to ¥19,130,957.99, marking a 213.46% increase year-over-year, with R&D expenses accounting for 18.97% of revenue[9] - Research and development expenses increased by 213.46% year-over-year, reflecting the company's commitment to advancing its projects[22] - The company plans to continue expanding its R&D efforts and product offerings to sustain growth in the upcoming quarters[12] - The company continues to invest in the development of new products, including PEG-irinotecan and other projects, to enhance its R&D pipeline[22] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 5,385, with the largest shareholder holding 14,866,610 shares[14] - The company adjusted the grant price of its restricted stock incentive plan from 41.18 yuan to 40.75 yuan per share[22] Assets and Liabilities - The total assets at the end of the reporting period were ¥1,160,654,182.59, a 5.40% increase from the end of the previous year[9] - The total assets of the company amounted to 1.16 billion yuan as of March 31, 2022, compared to 1.10 billion yuan at the end of 2021[25] - The company's total liabilities stood at 54.38 million yuan, an increase from 49.55 million yuan in the previous year[27] Revenue Breakdown - The main business revenue grew significantly, with product sales revenue at 90.14 million yuan, a 41.63% increase year-over-year[22] - Domestic sales revenue surged to 28.57 million yuan, marking a 93.80% increase from the same period last year[22] - The company reported a significant increase in technical service revenue, which reached 1.06 million yuan, up 71.64% year-over-year[22]

Dividend and Profit Distribution - The company plans to distribute a cash dividend of 8.79 RMB per 10 shares, totaling approximately 52,740,000 RMB, which represents 30% of the net profit attributable to shareholders for 2021[7]. - The total share capital for the dividend calculation is estimated at 60,000,000 shares, subject to adjustment based on the actual share capital on the dividend record date[7]. - The company has not proposed any capital reserve transfer to increase share capital or stock dividends for 2021[7]. - The company has a cash dividend policy that prioritizes cash dividends at a minimum of 80% for mature stages without major capital expenditures, 40% with major expenditures, and 20% for growth stages with major expenditures[198]. - The company must have positive distributable profits and no significant investment plans to qualify for cash dividends, with a minimum annual cash distribution of 10% of the current year's distributable profits[198]. Financial Performance - The company's total revenue for 2021 was approximately ¥351.19 million, representing an 88.18% increase compared to ¥186.62 million in the previous year[32]. - Net profit attributable to shareholders for 2021 was approximately ¥175.78 million, a 105.16% increase from ¥85.68 million in 2020[32]. - The net cash flow from operating activities for 2021 was approximately ¥118.23 million, reflecting a 51.16% increase from ¥78.22 million in the previous year[32]. - The company's total assets at the end of 2021 were approximately ¥1.10 billion, a 22.27% increase from ¥900.61 million at the end of 2020[32]. - The basic earnings per share for 2021 was ¥2.93, a 71.35% increase compared to ¥1.71 in 2020[34]. - The weighted average return on equity for 2021 was 18.47%, a slight decrease of 0.73 percentage points from 19.20% in 2020[34]. - The net profit attributable to shareholders increased by 105.16% year-on-year, while the net profit after deducting non-recurring gains and losses grew by 89.74%[37]. - Basic earnings per share increased by 57.83% year-on-year, with diluted earnings per share rising by 69.49%[37]. - The gross profit margin for the main business was 85.21% during the reporting period[78]. - The company's gross profit margin for 2021 was 85.21%, a decrease of 0.76 percentage points from the previous year[87]. Research and Development - The R&D expenditure as a percentage of total revenue for 2021 was 15.37%, an increase of 1.28 percentage points from 14.09% in 2020[34]. - The company invested a total of 53.97 million yuan in R&D, representing a 105.22% increase year-on-year, with R&D expenses accounting for 15.37% of sales revenue[47]. - The company submitted 17 new patent applications and obtained 12 new authorizations during the year[47]. - The company achieved a total R&D investment of ¥53,968,557.23, representing a 105.22% increase compared to the previous year[65]. - The number of R&D personnel increased to 58, representing 27.9% of the total workforce, up from 18.3% in the previous year[70]. - The company completed the development of 50 new structural derivatives and optimized 21 derivative products during the reporting period[126]. - The company is focusing on the development of innovative polyethylene glycol-modified drugs and medical devices, with ongoing R&D investments[78]. Market and Sales Performance - The company experienced rapid growth in domestic product sales due to increased orders from major clients, contributing to the overall revenue increase[34]. - International product sales also grew rapidly, driven by stable order increases from overseas clients and new product orders from newly developed customers[34]. - Domestic revenue was 165 million yuan, a 79.44% increase, primarily from increased sales of products and technical service fees[100]. - International revenue reached 186 million yuan, up 96.73%, due to stable order growth from overseas clients and new product orders[100]. - The top five customers accounted for 63.66% of total sales, with the largest customer contributing ¥5,655.49 million, or 16.10%[105]. Corporate Governance - The company has established a comprehensive corporate governance system, including rules for the shareholders' meeting, board of directors, and supervisory board, ensuring clear responsibilities and procedures[156]. - The company held a total of 4 shareholder meetings in 2021, including 1 annual meeting and 3 extraordinary meetings, ensuring compliance with legal regulations and protecting minority shareholders' rights[159]. - The board of directors convened 9 meetings in 2021, adhering to legal and regulatory requirements, which enhanced the board's operational standards and decision-making processes[159]. - The company disclosed significant information accurately and timely, maintaining transparency and protecting the interests of minority investors[156]. - The company implemented a strict insider information management system to limit the number of individuals with access to sensitive information[156]. Risks and Challenges - The company faces risks related to market competition and potential declines in gross profit margin due to rising production costs[78]. - The company faced a risk of increased tax rates if it fails to maintain its high-tech enterprise status, which currently allows for a 15% corporate income tax rate[81]. - The company's products are significantly impacted by U.S. trade policies, with 60.34% of sales revenue derived from the U.S. market[83]. Future Outlook and Strategy - The company plans to continue expanding its market presence and enhancing its product offerings through ongoing R&D efforts[34]. - The company aims to enhance its technical innovation capabilities and maintain a leading position in the PEG-derived drug industry by focusing on continuous innovation and exploring new application scenarios[145]. - Over the next three years, the company plans to strengthen its R&D capabilities by increasing investments in advanced equipment, research funding, and human resources to improve market responsiveness[149]. - The company will focus on the production and sales of PEG-derived drugs while providing technical services and preclinical solutions, aiming to accelerate the development of proprietary products[149]. - The company intends to enhance its market presence by increasing marketing investments and optimizing service processes to improve service quality[149].

Financial Performance - In 2021, the company's operating revenue reached ¥351,190,577.05, representing an increase of 88.18% compared to ¥186,622,625.68 in 2020[33]. - The net profit attributable to shareholders was ¥175,780,091.14 in 2021, up 105.16% from ¥85,678,928.62 in 2020[33]. - The net profit after deducting non-recurring gains and losses was ¥157,174,080.41, reflecting an increase of 89.74% compared to ¥82,834,678.71 in 2020[33]. - The net cash flow from operating activities was ¥118,234,668.15, a 51.16% increase from ¥78,220,725.99 in 2020[33]. - As of the end of 2021, the total assets amounted to ¥1,101,185,583.81, a 22.27% increase from ¥900,611,434.81 at the end of 2020[33]. - The net assets attributable to shareholders were ¥1,051,632,483.11, which is a 22.82% increase from ¥856,243,364.98 at the end of 2020[33]. - The basic earnings per share for 2021 were ¥2.93, representing a 71.35% increase from ¥1.71 in 2020[33]. - The comprehensive gross margin for the year was 85.21%, a decrease of 0.76 percentage points from the previous year[88]. - The company's total revenue for the reporting period increased by 88.18% year-on-year, driven by increased orders from domestic and international clients[36]. Research and Development - The R&D investment accounted for 15.37% of operating revenue, an increase of 1.28 percentage points from 14.09% in 2020[33]. - Research and development investment reached 53.97 million yuan, a 105.22% increase year-on-year, accounting for 15.37% of total sales revenue[45]. - The company submitted 17 new patent applications and obtained 12 new authorizations during the year[45]. - The company completed 21 process optimizations and developed 50 new structural derivatives during the reporting period[130]. - The number of R&D personnel increased to 58, representing 27.9% of the total workforce, up from 18.3% in the previous year[71]. - The company has filed 17 new invention patent applications and obtained 12 patents during the reporting period, bringing the total to 45 applications and 87 patents[63]. - The company is developing a PEGylated irinotecan project with a total investment of ¥76,500,000, currently in Phase II clinical trials[70]. - The company has established three core technology platforms to create a complete PEGylation technology ecosystem, targeting small molecule drugs, gene drugs, and medical devices[154]. Corporate Governance - The company has confirmed that all board members attended the board meeting, ensuring governance compliance[6]. - The company has not identified any special arrangements for corporate governance or significant matters affecting its operations[11]. - The governance structure includes a strategic committee, nomination committee, compensation and assessment committee, and audit committee to enhance decision-making[163]. - The company held a total of 4 shareholder meetings in 2021, including 1 annual meeting and 3 extraordinary meetings[162]. - The board of directors convened 9 meetings in 2021, ensuring compliance with legal regulations and internal rules[163]. - The supervisory board conducted 8 meetings in 2021, effectively overseeing the company's operations and financial status[163]. - The company disclosed significant information accurately and timely, maintaining transparency and protecting minority investors' interests[163]. - The company has established a comprehensive governance system to ensure the effective operation of the board and protect shareholder rights[163]. Market and Sales - The company's revenue mainly comes from the sales of PEG materials and related technical services, while self-developed PEG-modified drugs and Class III medical devices are still in preclinical or Phase II clinical research stages, generating no revenue yet[46]. - The company employs a direct sales model for both domestic and international markets, targeting well-known pharmaceutical companies and research institutions[50]. - The company's foreign sales revenue accounted for 52.88% of its main business income, with a foreign exchange loss of 2.14 million yuan reported during the period[86]. - The company's sales to the U.S. accounted for 60.34% of total sales, with potential impacts from U.S. trade protection policies and tariffs[86]. - The company achieved operating revenue of CNY 351.19 million, an increase of 88.18% compared to the same period last year[92]. - Domestic revenue was CNY 165.49 million, a 79.44% increase, primarily due to increased sales from major clients[99]. - International revenue reached CNY 185.70 million, a 96.73% increase, driven by stable order growth from overseas medical device clients[99]. Risks and Challenges - The company has outlined various operational risks and corresponding mitigation measures in the management discussion and analysis section[5]. - The company is exposed to risks related to international operations and potential changes in laws and regulations[79]. - The company faces risks related to the inability to meet customized client demands for polyethylene glycol derivatives[78]. - The company faced risks related to declining gross margins due to rising production costs and market competition[82]. - The company is advancing several innovative polyethylene glycol-modified drugs and medical devices, with ongoing R&D investments expected to impact profits[82]. Investment and Financial Management - The company plans to distribute a cash dividend of 8.79 RMB per 10 shares, totaling approximately 52,740,000 RMB, which represents 30% of the net profit attributable to shareholders for 2021[7]. - The total share capital for the dividend calculation is estimated at 60,000,000 shares, subject to adjustment based on the actual share capital on the dividend record date[7]. - The company reported a net cash outflow from investment activities of CNY 571.46 million, primarily due to significant capital expenditures on fixed and intangible assets[92]. - The company has implemented a cash management strategy using temporarily idle raised funds for financial products[188]. - The company plans to utilize temporarily idle raised funds for cash management, which will not affect the normal implementation of investment projects[196]. Strategic Initiatives - The company aims to enhance its technical innovation capabilities and maintain a leading position in the PEG-derived pharmaceutical industry by focusing on material innovation and exploring new application scenarios[152]. - The company plans to invest in R&D to strengthen its product development and technical service capabilities, with a focus on PEG-derived drugs and their applications in various fields[155]. - The company intends to expand its market presence by enhancing brand exposure and optimizing service processes in the pharmaceutical and medical device sectors[155]. - The company is actively pursuing mergers and acquisitions to strengthen its market position and diversify its product portfolio[178].

Financial Performance - The company's revenue for Q3 2021 reached ¥106,086,991, representing a 76.10% increase compared to the same period last year[8]. - Net profit attributable to shareholders for Q3 2021 was ¥61,726,591.95, marking a 117.91% year-over-year growth[8]. - The net profit excluding non-recurring gains and losses for Q3 2021 was ¥52,669,652.81, an increase of 86.61% compared to the same period last year[8]. - For the first three quarters of 2021, the company achieved total operating revenue of RMB 261.82 million, a year-on-year increase of 108.09%[27]. - The net profit attributable to shareholders for the same period was RMB 142 million, representing a year-on-year growth of 153.63%[27]. - The total operating revenue for the current period reached 166,026,268.80, compared to 65,529,345.98 in the previous period, marking an increase of approximately 153%[34]. - Net profit for the current period was 142,364,121.35, up from 56,129,850.29 in the previous period, representing an increase of about 153%[34]. - The total comprehensive income for the current period was 141,434,010.95, compared to 57,387,027.81 in the previous period, showing an increase of approximately 146%[37]. Assets and Liabilities - The total assets at the end of Q3 2021 amounted to ¥1,033,144,493.96, reflecting a 14.72% increase from the end of the previous year[12]. - As of September 30, 2021, the company's total assets amounted to RMB 1.03 billion, compared to RMB 900.61 million at the end of 2020[28]. - The total liabilities of the company were RMB 42.27 million, a slight decrease from RMB 44.37 million at the end of 2020[31]. - Total assets decreased from 909,497,719.62 to 900,611,434.81, a reduction of 8,886,284.81[42]. - Current liabilities increased from 43,940,050.79 to 41,311,742.98, a decrease of 2,628,307.81[42]. - Non-current liabilities rose significantly from 9,314,303.85 to 3,056,326.85, an increase of 6,257,977.00[42]. - Total liabilities increased from 53,254,354.64 to 44,368,069.83, a decrease of 8,886,284.81[42]. - Total equity remained stable at 856,243,364.98, unchanged from the previous period[42]. Shareholder Information - The total equity attributable to shareholders at the end of Q3 2021 was ¥990,873,504.51, a 15.72% increase from the end of the previous year[12]. - The equity attributable to shareholders of the parent company reached RMB 990.87 million, up from RMB 856.24 million at the end of 2020[31]. - Basic earnings per share for Q3 2021 were ¥1.03, up 80.70% from the same period last year[12]. - Basic earnings per share for the current period were 2.37, compared to 1.20 in the previous period, reflecting an increase of about 97.5%[37]. Research and Development - Research and development expenses for Q3 2021 totaled ¥18,202,600.78, which is a 63.09% increase year-over-year[12]. - Research and development expenses amounted to 36,333,277.16, compared to 20,895,510.09 in the previous period, reflecting an increase of approximately 74%[34]. Cash Flow - The cash flow from operating activities for the year-to-date period was ¥119,181,073.19, showing a significant increase of 221.49% compared to the previous year[12]. - Cash flow from operating activities generated a net amount of 119,181,073.19, significantly higher than 37,071,538.81 in the previous period[37]. - The company reported cash inflow from investment activities totaling 1,310,564,638.60, compared to 60,341,260.28 in the previous period, indicating a substantial increase[39]. - The company experienced a net cash decrease of 448,611,239.38 in cash and cash equivalents, contrasting with an increase of 575,431,331.71 in the previous period[39]. Market and Product Development - The company reported a significant increase in product orders and shipment volumes, contributing to the overall revenue growth[17]. - The company's main business revenue grew rapidly, with product sales revenue reaching RMB 231 million, up 106.43% year-on-year[27]. - Domestic sales revenue was RMB 92 million, an increase of 86.95% compared to the same period last year, while foreign sales revenue was RMB 139 million, up 121.69% year-on-year[27]. - The company plans to continue expanding its market presence and developing new products to drive future growth[25].